Table 3.

Univariable and multivariable analyses of NMA-haplo BMT

Variables	PFS		OS		Relapse		NRM
	HR (95% CI)	P	HR (95% CI)	P	SDHR (95% CI)	P	HR (95% CI)	P
Univariable*
Refined DRI group
Low risk	Ref		Ref		Ref		Ref
Intermediate risk	2.55 (1.67-3.87)	<.0001	2.23 (1.44-3.45)	.0004	3.32 (1.90-5.78)	<.0001	0.92 (0.49-1.74)	.80
High/very high risk	3.37 (2.10-5.41)	<.0001	2.86 (1.74-4.72)	.0001	5.29 (2.89-9.66)	<.0001	0.66 (0.26-1.65)	.37
HCT-CI score
0 (low risk)	NT†		Ref		NT		Ref
1-2 (intermediate risk)			1.11 (0.77-1.58)	.59			1.14 (0.55-2.34)	.73
≥3 (high risk)			1.27 (0.88-1.81)	.20			1.60 (0.78-3.25)	.20
Comorbidity-age index
0-2 (low risk)	NT†		Ref		NT		Ref
≥3 (high risk)			1.17 (0.89-1.55)	.26			1.37 (0.81-2.34)	.24
Multivariable*‡
Patient age by decade§	1.07 (0.96-1.18)	.24	1.10 (0.98-1.23)	.10	1.03 (0.92-1.16)	.56	1.22 (0.96-1.54)	.10
Refined DRI group
Low risk	Ref		Ref		Ref		Ref
Intermediate risk	2.34 (1.54-3.57)	.0001	2.11 (1.36-3.28)	.0009	3.30 (1.89-5.75)	<.0001	0.79 (0.42-1.49)	.47
High/very high risk	3.06 (1.90-4.92)	<.0001	2.79 (1.69-4.60)	.0001	5.27 (2.90-9.61)	<.0001	0.58 (0.23-1.50)	.26
Female donor for male patient (vs other)	1.26 (0.95-1.68)	.11	1.34 (0.99-1.81)	.06	1.33 (0.98-1.82)	.07	NR
Patient CMV positive (vs negative)	1.34 (1.03-1.74)	.03	1.31 (1.00-1.76)	.05	NR		1.56 (0.92-2.65)	.10
CD3+ dose ≥ 3.84 e7 /kg (vs less)	0.77 (0.59-1.01)	.06	NR		NR		NR

CMV, cytomegalovirus; NR, not retained in final model; NT, not tested; ref, reference category.

^*All models were stratified by BMT year (2002-2008 vs later).

^†Index is validated for NRM and OS only.

^‡All models also considered donor age (continuous), CMV matching, and for NRM and OS, the HCT-CI score.

^§Increasing age by decade as a continuous variable.